ICICI Securities maintains an Add rating on Metropolis Healthcare with a raised target price of Rs 2,335. Metropolis is acquiring Core Diagnostics for Rs 2.47 billion, boosting its presence in the oncology market and expanding into North and Eastern India. This acquisition is projected to enhance Metropolis's growth and profitability over the long term.
